Tocilizumab for Patients With Cancer and COVID-19 Disease

Clinical trial NCT04370834 · TERMINATED

Trial details

NCT number: NCT04370834
Sponsor: National Cancer Institute (NCI)
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm Pneumonia Pneumonitis Severe Acute Respiratory Distress Syndrome Symptomatic COVID-19 Infection Laboratory-Confirmed

Start date: 2020-05-28
Primary completion: 2021-01-14
Enrollment: 1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.